Stockwatch: Will Earnings Season Rescue The Sector?
This article was originally published in Scrip
Executive Summary
At the end of last week, snowfalls and blizzards engulfing the East Coast brought not just an early end to the working week and the first positive weekly stock market close of the year, but a weather system that postponed my trip to New York City and Philadelphia. It will probably take more than the optimism engendered by an early start to last weekend to reverse the dismal year-to-date performance of life science stocks. That would take a positive earnings season.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.